CSL has slashed its revenue projection for the fiscal year from $15.8 billion to $15.2 billion and i...
BUSINESS NEWS
May 11, 2026
CSL slashes revenue projection and takes $5B impairment as interim CEO flags R&D misses, market erosion
CSL has slashed its revenue projection for the fiscal year from $15.8 billion to $15.2 billion and is taking a $5 billion asset impairment.
2 views
0 likes
0 comments
CSL has slashed its revenue projection for the fiscal year from $15.8 billion to $15.2 billion and is taking a $5 billion asset impairment.
Author: Fierce Pharma
Read Original Article
